{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T04:47:06Z","timestamp":1772945226143,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008773","name":"Hainan Association for Science and Technology","doi-asserted-by":"publisher","award":["232102311175"],"award-info":[{"award-number":["232102311175"]}],"id":[{"id":"10.13039\/501100008773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273782"],"award-info":[{"award-number":["82273782"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bioorg.2026.109588","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:28:49Z","timestamp":1770049729000},"page":"109588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design and optimization of selective and potent LSD1 inhibitors with tranylcypromine-pyrimidine scaffold for the treatment of acute myeloid leukemia"],"prefix":"10.1016","volume":"173","author":[{"given":"Ming-Jie","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiqi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai-Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109588_bb0005","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.109588_bb0010","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2196482","article-title":"A review of treatment options employed in relapsed\/refractory AML","volume":"28","author":"Mohamed Jiffry","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.bioorg.2026.109588_bb0015","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/leu.2014.244","article-title":"Novel drugs for older patients with acute myeloid leukemia","volume":"29","author":"Montalban-Bravo","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.109588_bb0020","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-019-0774-x","article-title":"Recent drug approvals for acute myeloid leukemia","volume":"12","author":"Lai","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.109588_bb0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17746","article-title":"Updates on targeted therapies for acute myeloid leukemia","volume":"196","author":"Kayser","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bioorg.2026.109588_bb0030","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in previously untreated acute myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109588_bb0035","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.109588_bb0040","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1021\/acs.chemrev.6b00801","article-title":"Inhibitors of protein methyltransferases and demethylases","volume":"118","author":"\u00dcmit","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2026.109588_bb0045","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","article-title":"Histone demethylation mediated by the nuclear amine oxidase homolog LSD1","volume":"119","author":"Shi","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109588_bb0050","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1021\/acs.chemrev.8b00008","article-title":"Chemical and biochemical perspectives of protein lysine methylation","volume":"118","author":"Luo","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2026.109588_bb0055","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2217\/epi-2016-0009","article-title":"LSD1: biologic roles and therapeutic targeting","volume":"8","author":"Maiques-Diaz","year":"2016","journal-title":"Epigenomics"},{"key":"10.1016\/j.bioorg.2026.109588_bb0060","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2217\/epi-2017-0022","article-title":"A comprehensive review of lysine-specific demethylase 1 and its roles in cancer","volume":"9","author":"Hosseini","year":"2017","journal-title":"Epigenomics"},{"key":"10.1016\/j.bioorg.2026.109588_bb0065","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCRESAHA.120.318149","article-title":"Myofibroblast deficiency of LSD1 alleviates TAC-induced heart failure","volume":"129","author":"Huo","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.bioorg.2026.109588_bb0070","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ijc.25349","article-title":"Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers","volume":"128","author":"Hayami","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109588_bb0075","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.3748\/wjg.v18.i45.6651","article-title":"Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients","volume":"18","author":"Zhao","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bioorg.2026.109588_bb0080","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s10620-012-2552-2","article-title":"Positive expression of LSD1 and negative expression of E-cadherin correlate with metastasis and poor prognosis of colon cancer","volume":"58","author":"Ding","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bioorg.2026.109588_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118002","article-title":"LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition","volume":"10","author":"Nagasawa","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.109588_bb0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2014-04-569525","article-title":"Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms","volume":"124","author":"Niebel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109588_bb0095","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/OTT.S145971","article-title":"Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy","volume":"11","author":"Castelli","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bioorg.2026.109588_bb0100","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","article-title":"Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia","volume":"19","author":"Goardon","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109588_bb0105","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1021\/acs.jmedchem.3c02133","article-title":"Combination therapy and dual-target inhibitors based on LSD1: new emerging tools in cancer therapy","volume":"67","author":"Shen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109588_bb0110","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ab.2013.07.032","article-title":"CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1","volume":"442","author":"Lynch","year":"2013","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.bioorg.2026.109588_bb0115","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.molcel.2024.05.017","article-title":"An autoinhibitory switch of the LSD1 disordered region controls enhancer silencing","volume":"84","author":"Waterbury","year":"2024","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.109588_bb0120","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1021\/acs.jmedchem.1c02156","article-title":"Structure\u2013activity relationship study of indolin-5-yl-cyclopropanamine derivatives as selective lysine specific demethylase 1 (LSD1) inhibitors","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109588_bb0125","first-page":"643","article-title":"Tranylcypromine-based LSD1 inhibitors: structure-activity relationships","volume":"15","author":"Fioravanti","year":"2020","journal-title":"Antiproliferative Effects in Leukemia, and Gene Target Modulation, Chemmedchem"},{"key":"10.1016\/j.bioorg.2026.109588_bb0130","first-page":"665","article-title":"Pyrrole-and indole-containing tranylcypromine derivatives as novel lysine-specific demethylase 1 inhibitors active on cancer cells","volume":"6","author":"Rodriguez","year":"2015","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109588_bb0135","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cmdc.202000754","article-title":"Synthesis of carboxamides tranylcypromine analogues as LSD1 (KDM1A) inhibitors for AML","volume":"16","author":"Borrello","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.109588_bb0140","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.19.03250","article-title":"First-in-human phase I study of Iadademstat (ORY-1001): a first-in-class lysine-specific histone demethylase 1A inhibitor, in relapsed or refractory acute myeloid Leukemia","volume":"38","author":"Salamero","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109588_bb0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fonc.2018.00255","article-title":"Lysine-specific demethylase 1A as a promising target in acute myeloid Leukemia","volume":"8","author":"Daniela","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109588_bb0150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccell.2015.06.002","article-title":"A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC","volume":"28","author":"Mohammad","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109588_bb0155","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0959-8049(14)70338-7","article-title":"212 novel anti-tumor activity of targeted LSD1 inhibition by GSK2879552","volume":"50","author":"Mohammad","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109588_bb0160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-019-0811-9","article-title":"LSD1\/KDM1A inhibitors in clinical trials: advances and prospects","volume":"12","author":"Fang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.109588_bb0165","doi-asserted-by":"crossref","first-page":"14197","DOI":"10.1021\/acs.jmedchem.0c00919","article-title":"Tranylcypromine based lysine-specific demethylase 1 inhibitor: summary and perspective","volume":"63","author":"Dai","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109588_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117438","article-title":"L, Huang, discovery of novel tranylcypromine-indazole-based derivatives as LSD1 inhibitors for acute myeloid leukemia treatment","volume":"289","author":"Huang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109588_bb0175","doi-asserted-by":"crossref","first-page":"13409","DOI":"10.1021\/acs.jmedchem.4c01303","article-title":"Design, synthesis, and evaluation of the selective and orally active LSD1 inhibitor with the potential of treating heart failure","volume":"67","author":"Huang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109588_bb0180","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/1573406418666220509100356","article-title":"Structure-activity relationships of pyrimidine derivatives and their biological activity-a review","volume":"19","author":"Ramalakshmi","year":"2023","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109588_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127993","article-title":"Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors","volume":"41","author":"Huang","year":"2021","journal-title":"Biorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109588_bb0190","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1021\/bi0618621","article-title":"Trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1","volume":"46","author":"Schmidt","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2026.109588_bb0195","series-title":"Schrodinger Release 2013\u20132","year":"2013"},{"key":"10.1016\/j.bioorg.2026.109588_bb0200","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ccell.2018.02.002","article-title":"Ory-1001, a potent and selective covalent kdm1a inhibitor, for the treatment of acute leukemia","volume":"33","author":"Maes","year":"2018","journal-title":"Cancer Cell"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826001240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826001240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:00:46Z","timestamp":1772892046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826001240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"alternative-id":["S0045206826001240"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109588","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and optimization of selective and potent LSD1 inhibitors with tranylcypromine-pyrimidine scaffold for the treatment of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109588"}}